Literature DB >> 12045049

Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study.

Paul Mitchell1, Jie Jin Wang, Suriya Foran, Wayne Smith.   

Abstract

PURPOSE: To describe the 5-year incidence and progression of early and late age-related maculopathy (ARM) lesions.
DESIGN: Population-based cohort study. PARTICIPANTS: Three thousand six hundred fifty-four noninstitutionalized residents, aged 49 years or older, living in the Blue Mountains area west of Sydney, Australia, participated in the study during 1992 to 1994. The cohort was reexamined after 5 years (1997-1999). Excluding 543 participants who died since the baseline, 2335 (75%) survivors attended 5-year follow-up examinations.
METHODS: Retinal photographs from both examinations were graded using the Wisconsin ARM Grading System. Photographs of participants with any ARM lesions at either examination were regraded in detail using a modification of the side-by-side method developed for the Beaver Dam Eye Study. MAIN OUTCOME MEASURES: Incidence and progression of ARM lesions were defined in a similar manner to that used in the Beaver Dam Eye Study.
RESULTS: Incidence rates for all ARM lesions increased significantly with age. For late ARM lesions (geographic atrophy and neovascular ARM), the overall 5-year incidence was 1.1%. The combined late ARM incidence was 0.0%, 0.6%, 2.4%, and 5.4% for participants aged 60 years and younger, 60 to 69 years, 70 to 79 years, and 80 years and older at baseline, respectively. After excluding participants with either early or late ARM in either eye at baseline, the overall 5-year incidence of early ARM was 8.7%, including 3.2%, 7.4%, 18.3%, and 14.8% for the corresponding age groups. The incidence of neovascular ARM in women was double that for men (P = 0.1).
CONCLUSIONS: This study has documented the incidence of ARM lesions in an older Australian population. The slightly higher incidence of hyperpigmentation found in our population compared with the Beaver Dam Eye Study may be due to sample variability, or this could reflect real differences between the two populations. Our lower incidence of soft drusen could have resulted from our non-inclusion of intermediate soft drusen in the soft distinct and indistinct drusen categories.

Entities:  

Mesh:

Year:  2002        PMID: 12045049     DOI: 10.1016/s0161-6420(02)01055-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  63 in total

Review 1.  Epidemiology of age-related maculopathy: a review.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  New grading criteria allow for earlier detection of geographic atrophy in clinical trials.

Authors:  Hilary Smolen Brader; Gui-Shuang Ying; E Revell Martin; Maureen G Maguire
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-29       Impact factor: 4.799

3.  Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS).

Authors:  Burkhard Dasch; Andrea Fuhs; Joachim Schmidt; Thomas Behrens; Astrid Meister; Juergen Wellmann; Manfred Fobker; Daniel Pauleikhoff; Hans-Werner Hense
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life.

Authors:  Alex W Hewitt; V Swetha Jeganathan; Juanita E Kidd; Konrad Pesudovs; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

5.  Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal Imaging.

Authors:  Cyril Dutheil; Mélanie Le Goff; Audrey Cougnard-Grégoire; Sarra Gattoussi; Jean-François Korobelnik; Marie-Bénédicte Rougier; Cédric Schweitzer; Cécile Delcourt; Marie-Noëlle Delyfer
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

6.  Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study.

Authors:  Fridbert Jonasson; Diana E Fisher; Gudny Eiriksdottir; Sigurdur Sigurdsson; Ronald Klein; Lenore J Launer; Tamara Harris; Vilmundur Gudnason; Mary Frances Cotch
Journal:  Ophthalmology       Date:  2014-04-24       Impact factor: 12.079

7.  Combined effects of complement factor H genotypes, fish consumption, and inflammatory markers on long-term risk for age-related macular degeneration in a cohort.

Authors:  Jie Jin Wang; Elena Rochtchina; Wayne Smith; Ronald Klein; Barbara E K Klein; Tripti Joshi; Theru A Sivakumaran; Sudha Iyengar; Paul Mitchell
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

8.  Misclassification can explain most apparent regression of age-related macular degeneration: results from multistate models with misclassification.

Authors:  Ronald E Gangnon; Kristine E Lee; Barbara E K Klein; Sudha K Iyengar; Theru A Sivakumaran; Ronald Klein
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

9.  Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Chelsea E Myers; Stacy M Meuer; Ronald E Gangnon; Theru A Sivakumaran; Sudha K Iyengar; Kristine E Lee; Barbara E K Klein
Journal:  JAMA Ophthalmol       Date:  2013-03       Impact factor: 7.389

10.  Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium.

Authors:  Ronald Klein; Stacy M Meuer; Chelsea E Myers; Gabriëlle H S Buitendijk; Elena Rochtchina; Farzana Choudhury; Paulus T V M de Jong; Roberta McKean-Cowdin; Sudha K Iyengar; Xiaoyi Gao; Kristine E Lee; Johannes R Vingerling; Paul Mitchell; Caroline C W Klaver; Jie Jin Wang; Barbara E K Klein
Journal:  Ophthalmic Epidemiol       Date:  2014-02       Impact factor: 1.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.